Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cost Analysis of Cetuximab plus Radiotherapy versus Cisplatin plus Radiotherapy in Head and Neck Cancer
2007-002169-11Phase 4Completed
- Sponsor
- The Royal Wolverhampton NHS Trust
- Start
- Nov 2007
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in oropharyngeal squamous cell carcinoma (OPSCC), laryngeal squamous cell carcinoma (LSCC), squamous cell carcinoma of the hypopharynx and 1 more comparing Cetuximab plus radiotherapy (ERT) with Cisplatin plus radiotherapy (CRT) (2 arms). Primary endpoint: Mean overall cost of total therapy. Started Nov 2007; status: completed.
02
Drugs
cetuximabcisplatin
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)laryngeal squamous cell carcinoma (LSCC)squamous cell carcinoma of the hypopharynxhead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2007-002169-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002169-11.